TD Private Client Wealth LLC Acquires 167 Shares of DexCom, Inc. (NASDAQ:DXCM)

TD Private Client Wealth LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 62.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 433 shares of the medical device company’s stock after purchasing an additional 167 shares during the quarter. TD Private Client Wealth LLC’s holdings in DexCom were worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Cerity Partners LLC increased its holdings in DexCom by 190.0% during the third quarter. Cerity Partners LLC now owns 60,050 shares of the medical device company’s stock worth $4,026,000 after buying an additional 39,344 shares during the last quarter. Swedbank AB grew its position in shares of DexCom by 15.2% during the 3rd quarter. Swedbank AB now owns 213,864 shares of the medical device company’s stock valued at $14,337,000 after acquiring an additional 28,289 shares during the period. Daiwa Securities Group Inc. increased its stake in shares of DexCom by 0.6% during the 3rd quarter. Daiwa Securities Group Inc. now owns 77,099 shares of the medical device company’s stock worth $5,169,000 after purchasing an additional 490 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of DexCom in the 3rd quarter worth approximately $961,000. Finally, D.A. Davidson & CO. lifted its stake in DexCom by 22.4% in the third quarter. D.A. Davidson & CO. now owns 32,578 shares of the medical device company’s stock valued at $2,184,000 after purchasing an additional 5,969 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of recent research reports. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Canaccord Genuity Group increased their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Citigroup boosted their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 105,009 shares of company stock worth $8,044,178. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $72.13 on Thursday. The stock has a market cap of $28.19 billion, a P/E ratio of 50.44, a PEG ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business’s 50-day moving average price is $82.96 and its two-hundred day moving average price is $77.07. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $141.99.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.